Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16ClNO4 |
Molecular Weight | 357.788 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(O)=O)C2=C1
InChI
InChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
Molecular Formula | C19H16ClNO4 |
Molecular Weight | 357.788 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363
Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11906281 |
3.0 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20503989 |
10.0 nM [IC50] | ||
Target ID: CHEMBL4681 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23432095 |
100.0 nM [IC50] | ||
Target ID: CHEMBL1835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2547071 |
100.0 nM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
|||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12142058 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
|||
Primary | INDOCIN Approved UseTIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1). Launch Date-1.43942402E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2369 ng/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2 μg/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7762 ng × h/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.22 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDOMETHACIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting Sources: Page: p.152Nausea (mild) Anorexia (mild) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 11 patient) Sources: Pruritus (below serious, 5 patients) |
20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 34 patients) Sources: Vomiting (below serious, 11 patient) Constipation (below serious, 8 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Other AEs: Deep vein thrombosis, Headache... Other AEs: Deep vein thrombosis (serious, 1 patient) Sources: Headache (below serious, 13 patients) Pruritus (below serious, 1 patient) Presyncope (below serious, 5 patients) |
40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 36 patients) Sources: Vomiting (below serious, 12 patients) Constipation (below serious, 7 patients) Post procedural haemorrhage (below serious, 7 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Other AEs: Headache, Pruritus... Other AEs: Headache (below serious, 12 patients) Sources: Pruritus (below serious, 3 patients) |
40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Other AEs: Headache, Vomiting... Other AEs: Headache (below serious, 17 patients) Sources: Vomiting (below serious, 9 patients) |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Disc. AE: Cardiac thrombosis, Myocardial infarction... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (serious) Sources: Myocardial infarction (grade 3-5) Stroke (grade 3-5) Gastrointestinal disorder NOS (serious) Bleeding (grade 3-5) Ulceration (grade 3-5) Perforation stomach (grade 3-5) Perforation of intestine (grade 3-5) |
0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Other AEs: Gingival bleeding, Application site pruritus... Other AEs: Gingival bleeding (below serious, 1 patient) Sources: Application site pruritus (below serious, 1 patient) Inflammation (below serious, 1 patient) Nasopharyngitis (below serious, 1 patient) Ligament sprain (below serious, 1 patient) Rash (below serious, 2 patients) Drug eruption (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | Disc. AE | 0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Anorexia | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Nausea | mild Disc. AE |
0.9 g single, oral Overdose Dose: 0.9 g Route: oral Route: single Dose: 0.9 g Sources: Page: p.152 |
unhealthy, 15 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 15 Sex: F Population Size: 1 Sources: Page: p.152 |
Headache | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Pruritus | below serious, 5 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 11 patient | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Nausea | below serious, 34 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Constipation | below serious, 8 patients | 20 mg 3 times / day multiple, oral Dose: 20 mg, 3 times / day Route: oral Route: multiple Dose: 20 mg, 3 times / day Sources: |
unhealthy, adult n = 92 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 92 Sources: |
Pruritus | below serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Headache | below serious, 13 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Presyncope | below serious, 5 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Deep vein thrombosis | serious, 1 patient | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 91 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 91 Sources: |
Vomiting | below serious, 12 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Nausea | below serious, 36 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Constipation | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Post procedural haemorrhage | below serious, 7 patients | 40 mg 2 times / day multiple, oral Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 12 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Pruritus | below serious, 3 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 93 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 93 Sources: |
Headache | below serious, 17 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Vomiting | below serious, 9 patients | 40 mg 3 times / day multiple, oral Dose: 40 mg, 3 times / day Route: oral Route: multiple Dose: 40 mg, 3 times / day Sources: |
unhealthy, adult n = 94 Health Status: unhealthy Condition: Acute Postoperative Pain Age Group: adult Sex: M+F Population Size: 94 Sources: |
Bleeding | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Myocardial infarction | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation of intestine | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Perforation stomach | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Stroke | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Ulceration | grade 3-5 Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Cardiac thrombosis | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Gastrointestinal disorder NOS | serious Disc. AE |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Bursitis|Tendinitis|Gouty arthritis Sources: |
Application site pruritus | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Drug eruption | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Gingival bleeding | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Inflammation | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Ligament sprain | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Nasopharyngitis | below serious, 1 patient | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
Rash | below serious, 2 patients | 0.35 % 2 times / day multiple, topical Dose: 0.35 %, 2 times / day Route: topical Route: multiple Dose: 0.35 %, 2 times / day Sources: |
unhealthy n = 135 Health Status: unhealthy Condition: sprained ankle Population Size: 135 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Aspirin sensitivity: other drugs. | 1975 Feb |
|
[Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis]. | 1975 Feb |
|
[Intrahepatic cholestasis following treatment with penicillamine D and indomethacine]. | 1976 May 28 |
|
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem. | 1979 Sep 15 |
|
Seizures induced by NSAID. | 1999 Jan |
|
[Psychiatric side effects of non-steroidal anti-inflammatory agents]. | 1999 Jan-Feb |
|
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. | 1999 Jul |
|
Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. | 1999 Jul 6 |
|
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts. | 1999 Jun |
|
Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. | 1999 May |
|
Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents. | 1999 Nov |
|
Effect of anti-CD11b (alphaM-MAC-1) and anti-CD54 (ICAM-1) monoclonal antibodies on indomethacin induced chronic ileitis in rats. | 1999 Nov |
|
Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. | 1999 Nov |
|
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. | 1999 Oct 29 |
|
Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. | 1999 Sep |
|
Sulindac inhibits activation of the NF-kappaB pathway. | 1999 Sep 17 |
|
[Effect of carrageenan and indomethacin on the growth of a murine fibrosarcoma]. | 2000 |
|
Matrix metalloproteinases 2 and 9 in indomethacin-induced rat gastric ulcer. | 2000 |
|
The role of nitric oxide and prostaglandin E2 on the hyperalgesia induced by excitatory amino acids in rats. | 2000 Apr |
|
Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action? | 2000 Aug |
|
Chronic intrathecal cannulation enhances nociceptive responses in rats. | 2000 Aug |
|
Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion. | 2000 Feb |
|
Enhanced protein denaturation in indomethacin-treated cells. | 2000 Jan |
|
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. | 2000 Jan |
|
Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. | 2000 Jul |
|
Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus. | 2000 Jul |
|
Ibuprofen as effective as indomethacin for patent ductus arteriosus. | 2000 Jul 25 |
|
The influence of indomethacin on the acth secretion induced by central stimulation of adrenergic receptors. | 2000 Jun |
|
Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate. | 2000 Jun 15 |
|
Effects of hydrogen peroxide scavenger Catalase on villous microcirculation in the rat small intestine in a model of inflammatory bowel disease. | 2000 May |
|
Role of endothelin-converting enzyme-1 in the suppression of constitutive nitric oxide synthase in rat gastric mucosal injury by indomethacin. | 2000 Nov |
|
Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. | 2000 Nov |
|
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells. | 2000 Nov 17 |
|
Indomethacin inhibits the accumulation of tumor cells in mouse lungs and subsequent growth of lung metastases. | 2000 Nov-Dec |
|
A case of living-related kidney transplantation in Bartter's syndrome. | 2000 Oct |
|
Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. | 2001 |
|
Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. | 2001 Feb |
|
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | 2001 Jan |
|
Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. | 2001 Mar |
|
Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production. | 2001 Mar 9 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27988363
U251 cells were incubated for 24 h with different concentrations of indomethacin (0.03, 0.06, 0.13, 0.25, 0.5, 1 mkM), diclofenac (DIC),naproxen (NAP), or ketoprofen (KET), and the cell viability was assessed by MTT or crystal violet (CV) tests.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:39:30 UTC 2023
by
admin
on
Wed Jul 05 22:39:30 UTC 2023
|
Record UNII |
XXE1CET956
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000160
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-VATC |
QS01BC01
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-VATC |
QC01EB03
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
NCI_THESAURUS |
C54677
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
NDF-RT |
N0000175721
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
LIVERTOX |
NBK548001
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-ATC |
M02AA23
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
NDF-RT |
N0000175722
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-VATC |
QM01AB01
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-ATC |
M01AB01
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-ATC |
S01BC01
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-VATC |
QM02AA23
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-ATC |
S01CC02
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-VATC |
QM01AB51
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-ATC |
M01AB51
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
||
|
WHO-ATC |
C01EB03
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL6
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
DB00328
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
M6279
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | Merck Index | ||
|
5781
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | RxNorm | ||
|
D007213
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
Indomethacin
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
DTXSID9020740
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
SUB08180MIG
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
100000092758
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
49662
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
757061
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
1524
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
77541
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
1341001
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
3101
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
3715
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
INDOMETHACIN
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | Description: A white or a pale yellow, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS and ether R. Category: Analgesic; anti-inflammatory. Storage: Indometacin should be kept in a well-closed container, protected from light. Additional information: Indometacin exhibits polymorphism. The polymorph specified in the monograph corresponds to the crystal form of indometacin RS.Definition: Indometacin contains not less than 98.0% and not more than 101.0% of C19H16ClNO4, calculated with reference to the dried substance. | ||
|
1440
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
C576
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
53-86-1
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
1909
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
200-186-5
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY | |||
|
INDOMETACIN
Created by
admin on Wed Jul 05 22:39:30 UTC 2023 , Edited by admin on Wed Jul 05 22:39:30 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
DEGRADENT -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|